ASMBNasdaqPharmaceutical PreparationsFiscal year ends December 31

ASSEMBLY BIOSCIENCES, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$20.16+0.07 (+0.35%)

Close on Oct 19, 2026

Market cap: $380.09M
P/E (TTM): –
Dividend yield: –

ASSEMBLY BIOSCIENCES, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31
Revenue	72	29	7.16	0	6.25	79	16	15	9.02	0	–	–	–	–	–	–	–	–	–
Research & Development	65	56	49	70	69	107	86	73	44	33	18	11	15	20	25	1.85	2.94	–	–
General & Administrative	20	18	23	24	29	37	33	35	17	12	11	13	4.58	5.34	8.72	2.92	0.40	–	–
Operating Expenses	84	74	72	94	139	144	119	108	61	–	–	–	–	–	–	–	–	–	–
Operating Income	-12	-45	-65	-94	-133	-65	-103	-93	-52	-45	-30	-24	-20	-25	-34	-4.77	-3.34	–	–
Interest Expense	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.12	3.78	1.12	–	–
Interest & Investment Income	6.00	5.57	3.45	1.02	0.30	2.62	4.31	3.08	0.98	1.54	1.23	0.17	0.20	0.07	0.08	0.01	0.00	–	–
Other Non-Operating Income	6.00	5.57	3.45	1.02	0.30	2.62	4.31	3.08	0.37	0.40	1.20	0.17	0.20	0.07	-0.34	-11	-1.20	–	–
Merger & Restructuring Charges	–	–	0	1.10	1.61	3.84	2.09	–	–	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	–	–	–	0	42	0	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	0	-0.62	-1.14	-0.03	0	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	0	-0.14	0	-1.62	-0.01	-0.10	0	0	0	0.00	0	–	–	–	–	–	–	–
Pretax Income	-6.12	-40	-61	-93	-132	-62	-98	-90	-52	-45	-28	-24	–	–	–	–	–	–	–
Income Tax Expense	0	0.33	0.03	0	-2.53	0	-0.77	1.10	-9.05	-0.62	0	0	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-6.12	-40	-61	-93	-130	-62	-98	-91	-43	–	–	–	–	–	–	–	–	–	–
Net Income	-6.12	-40	-61	-93	-130	-62	-98	-91	-43	-44	-28	-24	-19	-25	-34	-15	-4.54	-8.79	-4.57
EPS (Basic)(per share)	-0.55	-6.69	-13.38	-23.08	-36.00	-21.00	-44.64	-47.76	-28.92	-30.84	-21.72	-40.80	-60.00	-116.40	-214.20	-1,480.20	-601.20	–	–
EPS (Diluted)(per share)	-0.55	-6.69	-13.38	-23.08	-36.00	-21.00	-44.64	-47.76	-28.92	-30.84	-21.72	-40.80	-60.00	-116.40	-214.20	-1,480.20	-601.20	–	–
Shares Outstanding (Basic, Weighted)(shares)	11	6.00	4.58	4.03	3.61	2.95	2.19	1.90	1.48	1.44	1.31	0.58	0.32	0.21	0.16	0.01	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	11	6.00	4.58	4.03	3.61	2.95	2.19	1.90	1.48	1.44	1.31	0.58	0.32	0.21	0.16	0.01	–	–	–
EBITDA	-12	-45	-64	-94	-132	-64	-102	-92	-52	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -11.8%
Net margin: -0.1%
Return on equity, FY2025: -5.1%

Financial strength

Current ratio: 13.99
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 137.7%

Valuation

P/E ratio: –
Price to sales: 5.08
Price to book: 1.24
Dividend yield: –